Financial Incentives for Smoking Cessation in Pregnant Women
BACKGROUND AND PURPOSE:
Berlin et al. (BMJ, 2021) evaluated the efficacy of financial incentives to promote smoking cessation
Single blind, randomized controlled trial
Financial Incentive for Smoking Cessation in Pregnancy (FISCP)
18 maternity hospitals in France
Pregnant <18 weeks
≥18 years who smoked either
≥5 cigarettes/day or ≥3 roll-your-own cigarettes/day
Motivated to quit
Financial incentives group
Received a voucher equivalent to €20 (£17; $23), and further progressively increasing vouchers at each study visit if they remained abstinent
Received no financial incentive for abstinence
All participants received a €20 show-up fee at each of six visits
Visit 1: Quit date at randomization
Visits 2 to 6: Monthly face-to-face planned up until delivery
Continuous smoking abstinence from the first post-quit date visit to visit 6
Point prevalence abstinence (self-report of no smoking in the past seven days and expired air carbon monoxide (eCO) ≤8 ppm) | Time to smoking relapse | Withdrawal symptoms | Blood pressure | Alcohol and cannabis use in past 30 days
Gestational age at birth | Birth characteristics (birth weight, length, head circumference, Apgar score) | Poor neonatal outcome (a composite measure of transfer to the neonatal unit, congenital malformation, convulsions, or perinatal death)
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan